Mafosfamide
Appearance
| Names | |
|---|---|
| IUPAC name
2-{(2-[bis(2-chloroethyl)amino]-2-oxido-1,3,2-oxazaphosphinan-4-yl}thio)ethanesulfonic acid
| |
| Other names
2-{[2-[bis(2-chloroethyl)amino]-2-oxo-1-oxa-3-aza-2λ5-phosphacyclohex-4-yl}sulfanyl]ethanesulfonic acid ASTA-Z-7557
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChemSpider | |
| MeSH | Mafosfamide |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C9H19Cl2N2O5PS2 | |
| Molar mass | 401.25 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Mafosfamide (INN; development code ASTA-Z-7557) is an oxazaphosphorine (cyclophosphamide-like) alkylating agent under investigation as a chemotherapeutic. It is metabolized by cytochrome P450 into 4-hydroxycyclophosphamide, which is then converted into aldophosphamide, which, in turn yields the cytotoxic metabolites phosphoramide mustard and acrolein.[1]
Several Phase I trials have been completed.[2][3]
References
[edit]- ^ Ludeman SM (Aug 1999). "The chemistry of the metabolites of cyclophosphamide". Curr Pharm Des. 5 (8): 627–43. PMID 10469895.
- ^ "Intrathecal Mafosfamide". ClinicalTrials.gov. U.S. National Institutes of Health. August 21, 2006. Retrieved 2007-07-13. ClinicalTrials.gov Identifier NCT00062881.
- ^ "Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors". ClinicalTrials.gov. U.S. National Institutes of Health. February 20, 2007. Retrieved 2007-07-13. ClinicalTrials.gov Identifier NCT00031928.
Further reading
[edit]- Prous, J. R. (1983). "ASTA-Z-7557". Drugs of the Future. 8 (10): 839. doi:10.1358/dof.1983.008.10.61900. ISSN 0377-8282.

